Kinney Horn is a Director in Business Development at Genentech with twenty years of experience in life science finance, investment and biopharmaceutical business development roles.
Kinney’s transaction experience includes both in-licensing, out-licensing and mergers and acquisitions. He has a strong record of identifying pre-clinical and clinical stage opportunities, structuring strategic alliances, negotiating and closing deals, and managing contractual relationships. His international experience includes negotiations with European and Asian companies.
Kinney’s primary responsibilities and transactions relate to leading teams for the licensing and acquisition of products and technologies. He has also led teams responsible for outlicensing selected Genentech products.
Selected transactions include:
-the $1.7B acquisition of Seragon Pharmaceuticals;
-key product and pre-clinical technology collaborations (representing over $20B in value) with Hanmi, Immunocore, Seattle Genetics, Vernalis, NCM and Spirogen; and
- out-licensing of clinical-stage products to Curis, Bio-Clin and Tercica
In addition to corporate transaction responsibilities, Kinney has led the annual oncology strategic sourcing process for 13 areas of oncology research and development, developed a "Teaching Culture" curriculum and activities for Genentech's ~80 FTE community of transaction professionals, hired, managed and mentored individuals and is an active speaker in the biotechnology conference and partnering community.
Prior to Roche’s acquisition of Genentech, Kinney worked with early stage biotechnology companies that Genentech had invested in through GenenFUND, Genentech’s private equity fund.
From 2003 to 2005, he held positions of increasing responsibility supporting 10 molecules in Genentech's portfolio, the B-cell franchise core team as a Sr. Financial Analyst, and Business Development transactions as a Finance Manager.